September 19, 2018 09:57 AM EDT
Financing

Two Genen­tech vets re­unite at Im­mune-Onc to help steer its $33M dri­ve to the clin­ic

Amber Tong

Look for yet an­oth­er play­er work­ing in the im­muno-on­col­o­gy space to en­ter the clin­ic with a nim­ble team of ex­pe­ri­enced ex­ecs fo­cused on dis­man­tling im­muno­sup­pres­sion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times